Although only ICEC0942 among these four CDK inhibitors is a BS-181 analog that has been developed to retain the CDK7 selectivity of BS-181 [44], and is thus highly likely to induce extrinsic apoptosis through TRAIL/DR5 upregulation in tumor cells, the contributions of these CDK7 inhibitors to the extrinsic TRAIL/DR5-dependent apoptosis induction in tumor cells and their synergistic cytotoxic effect exerted by cotreatment with rTRAIL remain to be elucidated. The gene discussed is TNFRSF10B; the disease is neoplasm.